Most sold healthcare stocks in Q4 2018

See which Healthcare stocks institutional investors trimmed or exited the most in Q4 2018, measured as net reductions in reported share positions from Q3 2018 into Q4 2018. Notable reductions at the top of this list include NOVARTIS AG-SPONSORED ADR (NVS), ELI LILLY & CO (LLY), BAXTER INTERNATIONAL INC (BAX), PACIFIC BIOSCIENCES OF CALIF (PACB). These rankings are based on SEC 13F filings from the investors we track.

SymbolNameNet sharesNet valueNewAddedTrimmedSold outHolding now
NVSNOVARTIS AG-SPONSORED ADR-11,651,735-$1.07M02608
LLYELI LILLY & CO-8,382,235-$761.91K11305
BAXBAXTER INTERNATIONAL INC-8,002,480-$942.04K00305
PACBPACIFIC BIOSCIENCES OF CALIF-7,625,895-$40.94K10102
TMOTHERMO FISHER SCIENTIFIC INC-4,741,058-$1.22M018111
DHRDANAHER CORP-3,597,769-$471.47K00517
PFEPFIZER INC-3,430,553-$509.81K01819
MRKMERCK & CO. INC.-3,403,658-$181.83K108011
CAHCARDINAL HEALTH INC-3,251,794-$246.54K01405
ELANELANCO ANIMAL HEALTH INC-2,664,173-$92.95K00020
XRAYDENTSPLY SIRONA INC-2,162,022-$85.60K01214
CORCENCORA INC-1,773,213-$271.04K10203
AZNASTRAZENECA PLC-SPONS ADR-1,651,108-$144.06K00111
MCKMCKESSON CORP-1,253,582-$396.76K11316
ABBVABBVIE INC-1,166,426-$111.05K02318
CVSCVS HEALTH CORP-1,070,492-$577.13K22509
SNYSANOFI-ADR-919,840-$117.54K00212
AMGNAMGEN INC-902,538-$248.09K01506
VCYTVERACYTE INC-806,989$4.64K00202
PDCOPATTERSON COS INC-670,335-$23.67K00202
JNJJOHNSON & JOHNSON-651,524-$211.27K038014
SIGASIGA TECHNOLOGIES INC-602,886-$4.16K00010
HALOHALOZYME THERAPEUTICS INC-470,363-$17.42K01304
ISRGINTUITIVE SURGICAL INC-466,164-$325.19K02204
CNCCENTENE CORP-441,997-$104.63K03114
GKOSGLAUKOS CORP-429,405-$29.11K00101
HOLXHOLOGIC INC-418,384-$1.09M10304
RMDRESMED INC-414,476-$48.41K00101
ADAPADAPTIMMUNE THERAPEUTICS-ADR-407,500-$10.42K00101
VEEVVEEVA SYSTEMS INC-CLASS A-388,096-$62.66K00101
IQVIQVIA HOLDINGS INC-381,947-$180.76K02103
AXGNAXOGEN INC-355,900-$17.31K00101
RDNTRADNET INC-330,913-$13.98K00101
IDXXIDEXX LABORATORIES INC-307,170-$173.59K00305
MEDPMEDPACE HOLDINGS INC-296,400-$21.17K00101
EBSEMERGENT BIOSOLUTIONS INC-275,300-$28.58K00101
WATWATERS CORP-272,012-$69.29K01314
ABTABBOTT LABORATORIES-270,136-$23.26K00306
HCAHCA HEALTHCARE INC-259,077-$72.67K01102
MDXGMIMEDX GROUP INC-222,973-$3.50K00101
BCRXBIOCRYST PHARMACEUTICALS INC-217,203-$1.66K00010
EGRXEAGLE PHARMACEUTICALS INC-213,822-$14.82K00010
IARTINTEGRA LIFESCIENCES HOLDING-209,800-$16.90K00101
BLUEBLUEBIRD BIO INC-203,706-$38.96K00101
CTMXCYTOMX THERAPEUTICS INC-202,700-$8.23K00101
SGRYSURGERY PARTNERS INC-201,800-$3.54K00101
PTGXPROTAGONIST THERAPEUTICS INC-197,400-$3.24K00101
NTRANATERA INC-192,796-$17.95K00101
ADMAADMA BIOLOGICS INC-188,300-$1.17K00010
UHSUNIVERSAL HEALTH SERVICES-B-180,418-$56.51K01112
20 symbols with net change in reported shares from tracked managers.−12.8M−9.6M−6.4M−3.2M0.00Net change in reported shares (tracked managers)NVSLLYBAXPACBTMODHRPFEMRKCAHELANXRAYCORAZNMCKABBVCVSSNYAMGNVCYTPDCOSymbol

Frequently asked questions about Most sold healthcare stocks in Q4 2018

  • What are the most sold Healthcare stocks in Q4 2018?

    The most sold healthcare stocks in Q4 2018 are those with the largest decrease in reported share counts across tracked institutional investors compared to Q3 2018, based on SEC 13F filings.

  • Which healthcare stocks did institutional investors trimmed or exited the most in Q4 2018?

    Among the managers we track, net reductions were largest in companies such as NOVARTIS AG-SPONSORED ADR (NVS), ELI LILLY & CO (LLY), BAXTER INTERNATIONAL INC (BAX), based on aggregated 13F data.

  • How is institutional selling calculated?

    Selling is calculated by summing the net decrease in shares reported by tracked investors between two consecutive quarterly 13F snapshots (compared to Q3 2018).

  • Does this include all institutional owners?

    These rankings are based on a subset of tracked institutional investors who file SEC 13F reports. While not exhaustive, the dataset includes many of the largest and most influential funds.

  • Are these trades real-time?

    No. 13F filings are reported quarterly and may be delayed by up to 45 days. The data reflects positions at the end of the reporting period, not real-time trading activity.